EuroEyes International Eye Clinic (SEHK:1846) Margin Compression Challenges Bullish Growth Narrative

EuroEyes International Eye Clinic (SEHK:1846) has posted its FY 2025 first half results with total revenue of HK$377.1 million and basic EPS of HK$0.12, setting the tone for how the rest of the year may shape up. The company has seen revenue move from HK$368.4 million in 1H 2024 to HK$377.1 million in 1H 2025, while basic EPS shifted from HK$0.13 to HK$0.12 over the same period. Trailing 12 month basic EPS sits at HK$0.24 on revenue of HK$724.4 million. With a trailing net profit margin of 10.6% and a recent one off gain in the mix, the key question for investors is how durable these margins look as the business moves through FY 2025.

See our full analysis for EuroEyes International Eye Clinic.

With the headline numbers in place, the next step is to see how this earnings story lines up with the dominant narratives around EuroEyes International Eye Clinic and where those stories may need adjusting.

See what the community is saying about EuroEyes International Eye Clinic

Margins Ease Back From 14.7% To 10.6%

• The trailing net profit margin is 10.6%, compared with 14.7% a year earlier, on trailing revenue of HK$724.4 million and net income (excluding extra items) of HK$76.5 million.
• Critics highlight a bearish concern that multi year earnings have declined 2.7% per year, and the lower margin adds to that. Yet the consensus narrative also points to new clinics and lens based treatments as longer term supports:
  • The five year 2.7% annual earnings decline and the step down from a 14.7% margin frame the bear case around earnings pressure.
  • At the same time, investments in presbyopia focused treatments and new clinics in locations like Hong Kong and London are cited in the consensus view as potential ways to improve revenue and margins over time, even if those benefits are not reflected in the current 10.6% margin.

Skeptics who focus on the margin drop may want to see how the full bear case stacks these figures against the long term story before deciding what really matters most. 🐻 EuroEyes International Eye Clinic Bear Case

Revenue Holds In The HK$724 Million Range

• Over the trailing 12 months, EuroEyes recorded HK$724.4 million in revenue and HK$76.5 million in net income (excluding extra items), compared with HK$715.7 million revenue and HK$82.3 million net income in the prior trailing period.
• The analysts' consensus narrative leans bullish on growth from presbyopia and new clinics, and these revenue levels provide a reality check on that story:
  • Revenue in the HK$724 million range is aligned with the idea of a larger procedure base, which the consensus links to lens based treatments and geographic diversification across Germany, the U.K., Denmark and China.
  • However, the move from HK$82.3 million to HK$76.5 million in trailing net income means earnings have not kept pace with revenue, challenging the part of the bullish view that expects investments in new clinics to translate quickly into higher profitability.

Low 11.3x P/E Versus Peers

• The shares trade on a trailing P/E of 11.3x, below the Hong Kong healthcare industry average of 13.5x and the peer average of 26.4x, while the current share price of HK$2.70 also sits well below both the analyst price target of HK$5.80 and a DCF fair value of HK$12.81.
• Supporters of a more bullish stance argue the low multiple and the gap to HK$5.80 and HK$12.81 suggest mispricing, but the bear narrative points back to the earnings record:
  • The 2.7% annual earnings decline over five years and the inclusion of a HK$24.7 million one off gain in trailing results give bears a concrete reason to say the 11.3x P/E might be a fair reflection of mixed earnings quality.
  • On the other hand, those leaning bullish see the discount to the 13.5x industry multiple, the HK$5.80 price target and the HK$12.81 DCF fair value as evidence that the market could be underestimating the effect of presbyopia treatments and M&A plans on future earnings.

If you are weighing whether that 11.3x P/E is a trap or an opportunity, it helps to see how bulls connect these earnings and valuation numbers into a bigger picture for the business. 🐂 EuroEyes International Eye Clinic Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for EuroEyes International Eye Clinic on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, that is the point. Investors are weighing both sides in real time, so move quickly, review the latest data and form your own take using the 1 key reward and 2 important warning signs

See What Else Is Out There

EuroEyes is facing pressure from lower net profit margins, a multi year 2.7% annual earnings decline and reliance on a recent one off gain in earnings.

If you are concerned about that earnings track record and want ideas with stronger fundamentals and valuation support, check out the 247 high quality undervalued stocks to compare alternatives side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com